{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T02:28:37Z","timestamp":1780712917991,"version":"3.54.1"},"reference-count":50,"publisher":"Impact Journals, LLC","issue":"44","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,9,29]]},"DOI":"10.18632\/oncotarget.20845","type":"journal-article","created":{"date-parts":[[2017,9,12]],"date-time":"2017-09-12T22:41:17Z","timestamp":1505256077000},"page":"77872-77882","source":"Crossref","is-referenced-by-count":31,"title":["Cancer antigen profiling for malignant pleural mesothelioma immunotherapy: expression and coexpression of mesothelin, cancer antigen 125, and Wilms tumor 1"],"prefix":"10.18632","volume":"8","author":[{"given":"Takashi","family":"Eguchi","sequence":"first","affiliation":[{"name":"Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA"},{"name":"Division of Thoracic Surgery, Department of Surgery, Shinshu University School of Medicine, Matsumoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyuichi","family":"Kadota","sequence":"additional","affiliation":[{"name":"Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA"},{"name":"Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA"},{"name":"Department of Diagnostic Pathology, Faculty of Medicine, Kagawa University, Kagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marissa","family":"Mayor","sequence":"additional","affiliation":[{"name":"Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjorie G.","family":"Zauderer","sequence":"additional","affiliation":[{"name":"Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Rimner","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie W.","family":"Rusch","sequence":"additional","affiliation":[{"name":"Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William D.","family":"Travis","sequence":"additional","affiliation":[{"name":"Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Sadelain","sequence":"additional","affiliation":[{"name":"Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasad S.","family":"Adusumilli","sequence":"additional","affiliation":[{"name":"Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA"},{"name":"Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2017,9,12]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0140-6736(05)67025-0","article-title":"Malignant mesothelioma","volume":"366","author":"Lake","year":"2005","journal-title":"Lancet"},{"key":"2","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1183\/09031936.00039510","article-title":"Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial","volume":"36","author":"van Meerbeeck","year":"2010","journal-title":"Eur Respir J"},{"key":"3","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1200\/JCO.2008.20.3943","article-title":"Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma","volume":"27","author":"Vogelzang","year":"2009","journal-title":"J Clin Oncol"},{"key":"4","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.jtcvs.2015.09.129","article-title":"Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma","volume":"151","author":"Cho","year":"2016","journal-title":"J Thorac Cardiovasc Surg"},{"key":"5","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1200\/JCO.2016.67.2675","article-title":"Phase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) As Part of Lung-Sparing Multimodality Therapy in Patients With Malignant Pleural Mesothelioma","volume":"34","author":"Rosenzweig","year":"2016","journal-title":"J Clin Oncol"},{"key":"6","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1093\/annonc\/mdm093","article-title":"Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma","volume":"18","author":"Mingrone","year":"2007","journal-title":"Ann Oncol"},{"key":"7","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S1470-2045(11)70149-8","article-title":"Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study","volume":"12","author":"Spicer","year":"2011","journal-title":"Lancet Oncol"},{"key":"8","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1016\/S1470-2045(15)00208-9","article-title":"Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17\/04): a randomised, international, multicentre phase 2 trial","volume":"16","author":"Mordasini","year":"2015","journal-title":"Lancet Oncol"},{"key":"9","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.jtcvs.2015.09.086","article-title":"What is the best approach for surgery of malignant pleural mesothelioma? It is to put our efforts into obtaining trustworthy evidence for practice","volume":"151","author":"Treasure","year":"2016","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Gustafson","year":"2016","journal-title":"Nat Genet"},{"key":"11","first-page":"8","article-title":"New therapeutic strategies for malignant pleural mesothelioma","volume":"123","author":"Alfieri","year":"2016","journal-title":"Biochem Pharmacol"},{"key":"12","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jtcvs.2007.10.026","article-title":"Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma","volume":"135","author":"de Perrot","year":"2008","journal-title":"J Thorac Cardiovasc Surg"},{"key":"13","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1007\/s00262-010-0881-6","article-title":"CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection","volume":"59","author":"Nishimura","year":"2010","journal-title":"Cancer Immunol Immunother"},{"key":"14","doi-asserted-by":"crossref","first-page":"e1009285","DOI":"10.1080\/2162402X.2015.1009285","article-title":"The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: A comprehensive analysis reveals prognostic immune markers","volume":"4","author":"Adusumilli","year":"2015","journal-title":"Oncoimmunology"},{"key":"15","doi-asserted-by":"crossref","first-page":"e106742","DOI":"10.1371\/journal.pone.0106742","article-title":"Ratio of intratumoral macrophage phenotypes is a prognostic factor in epithelioid malignant pleural mesothelioma","volume":"9","author":"Aerts","year":"2014","journal-title":"PLoS One"},{"key":"16","first-page":"208ra147","article-title":"Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression","volume":"5","author":"Pastan","year":"2013","journal-title":"Sci Transl Med"},{"key":"17","doi-asserted-by":"crossref","first-page":"261ra151","DOI":"10.1126\/scitranslmed.3010162","article-title":"Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity","volume":"6","author":"Sadelain","year":"2014","journal-title":"Sci Transl Med"},{"key":"18","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The basic principles of chimeric antigen receptor design","volume":"3","author":"Riviere","year":"2013","journal-title":"Cancer Discov"},{"key":"19","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/PPO.0000000000000040","article-title":"Novel approaches to enhance the specificity and safety of engineered T cells","volume":"20","author":"Kloss","year":"2014","journal-title":"Cancer J"},{"key":"20","first-page":"133","article-title":"Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors","volume":"6","author":"Adusumilli","year":"2015","journal-title":"Cancer Discov"},{"key":"21","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1158\/1078-0432.CCR-13-1862","article-title":"Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence-free and overall survival in early-stage lung adenocarcinoma","volume":"20","author":"Adusumilli","year":"2014","journal-title":"Clin Cancer Res"},{"key":"22","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1158\/1055-9965.EPI-11-0993","article-title":"Tissue and serum mesothelin are potential markers of neoplastic progression in Barrett's associated esophageal adenocarcinoma","volume":"21","author":"Adusumilli","year":"2012","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"23","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1158\/1078-0432.CCR-11-2614","article-title":"Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients","volume":"18","author":"Adusumilli","year":"2012","journal-title":"Clin Cancer Res"},{"key":"24","doi-asserted-by":"crossref","first-page":"e114900","DOI":"10.1371\/journal.pone.0114900","article-title":"Mesothelin expression in triple negative breast carcinomas correlates significantly with basal-like phenotype, distant metastases and decreased survival","volume":"9","author":"Wen","year":"2014","journal-title":"PLoS One"},{"key":"25","doi-asserted-by":"crossref","first-page":"e26839","DOI":"10.1371\/journal.pone.0026839","article-title":"Pathobiological implications of MUC16 expression in pancreatic cancer","volume":"6","author":"Batra","year":"2011","journal-title":"PLoS One"},{"key":"26","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1440-1827.2007.02080.x","article-title":"Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma","volume":"57","author":"Inai","year":"2007","journal-title":"Pathol Int"},{"key":"27","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.cllc.2011.03.019","article-title":"Serum tumor markers CEA, CYFRA21-1, and CA-125 are associated with worse prognosis in advanced non-small-cell lung cancer (NSCLC)","volume":"12","author":"Felip","year":"2011","journal-title":"Clin Lung Cancer"},{"key":"28","doi-asserted-by":"crossref","first-page":"9190","DOI":"10.1074\/jbc.M312372200","article-title":"Binding of ovarian cancer antigen CA125\/MUC16 to mesothelin mediates cell adhesion","volume":"279","author":"Miyajima","year":"2004","journal-title":"J Biol Chem"},{"key":"29","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1476-4598-5-50","article-title":"Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors","volume":"5","author":"Patankar","year":"2006","journal-title":"Mol Cancer"},{"key":"30","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/j.1349-7006.2012.02214.x","article-title":"Coexpression of MUC16 and mesothelin is related to the invasion process in pancreatic ductal adenocarcinoma","volume":"103","author":"Yamaue","year":"2012","journal-title":"Cancer Sci"},{"key":"31","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1038\/srep01870","article-title":"Mesothelin binding to CA125\/MUC16 promotes pancreatic cancer cell motility and invasion via MMP-7 activation","volume":"3","author":"Konstantopoulos","year":"2013","journal-title":"Sci Rep"},{"key":"32","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1158\/1078-0432.CCR-11-2121","article-title":"A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction","volume":"18","author":"Sugar","year":"2012","journal-title":"Clin Cancer Res"},{"key":"33","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1084\/jem.20031435","article-title":"Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients","volume":"200","author":"Jaffee","year":"2004","journal-title":"J Exp Med"},{"key":"34","first-page":"3234","article-title":"Interleukin-6 fused to an anti-idiotype antibody in a vaccine increases the specific humoral immune response against CA125+ (MUC-16) ovarian cancer","volume":"63","author":"Wagner","year":"2003","journal-title":"Cancer Res"},{"key":"35","first-page":"20","article-title":"Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin","volume":"7","author":"Iacobuzio-Donahue","year":"2007","journal-title":"Cancer Imm"},{"key":"36","doi-asserted-by":"crossref","first-page":"5927","DOI":"10.1158\/1078-0432.CCR-14-0804","article-title":"Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma","volume":"20","author":"Wallin","year":"2014","journal-title":"Clin Cancer Res"},{"key":"37","first-page":"3311","article-title":"Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125","volume":"20","author":"Pastan","year":"2014","journal-title":"Cancer"},{"key":"38","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/sj.leu.2403817","article-title":"Wilms\u2019 tumour gene 1 (WT1) in human neoplasia","volume":"19","author":"Sugiyama","year":"2005","journal-title":"Leukemia"},{"key":"39","first-page":"344","article-title":"Wilms\u2019 tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma","volume":"146","author":"Albelda","year":"1995","journal-title":"Am J Pathol"},{"key":"40","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/(SICI)1096-9896(199701)181:1<67::AID-PATH723>3.0.CO;2-Z","article-title":"WT1 mutation in malignant mesothelioma and WT1 immunoreactivity in relation to p53 and growth factor receptor expression, cell-type transition, and prognosis","volume":"181","author":"Van Marck","year":"1997","journal-title":"J Pathol"},{"key":"41","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1007\/s00262-010-0871-8","article-title":"WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer","volume":"59","author":"Scheinberg","year":"2010","journal-title":"Cancer Immunol Immunother"},{"key":"42","article-title":"Randomized phase II study of adjuvant WT1 vaccine (SLS-001) for malignant pleural mesothelioma (MPM) after multimodality therapy","volume":"34","author":"Krug","year":"2016","journal-title":"J Clin Oncol"},{"key":"43","doi-asserted-by":"crossref","first-page":"e1119354","DOI":"10.1080\/2162402X.2015.1119354","article-title":"Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival","volume":"5","author":"Wels","year":"2016","journal-title":"Oncoimmunol"},{"key":"44","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1038\/mt.2013.185","article-title":"Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma","volume":"21","author":"Wu","year":"2013","journal-title":"Mol Ther"},{"key":"45","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1172\/JCI83416","article-title":"Tandem CAR T cells targeting HER2 and IL13Ralpha2 mitigate tumor antigen escape","volume":"126","author":"Krebs","year":"2016","journal-title":"J Clin Invest"},{"key":"46","doi-asserted-by":"crossref","unstructured":"Rusch, Giroux, Kennedy, Ruffini, Cangir, Rice, Pass, Asamura, Waller, Edwards, Weder, Hoffmann, van Meerbeeck. Initial Analysis of the International Association For the Study of Lung Cancer Mesothelioma Database. J Thorac Oncol. 2012; 7:1631\u20131639.","DOI":"10.1097\/JTO.0b013e31826915f1"},{"key":"47","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1097\/JTO.0b013e318211127a","article-title":"Pleomorphic epithelioid diffuse malignant pleural mesothelioma: a clinicopathological review and conceptual proposal to reclassify as biphasic or sarcomatoid mesothelioma","volume":"6","author":"Travis","year":"2011","journal-title":"J Thorac Oncol"},{"key":"48","volume-title":"World Health Organization Classification of Tumours of the Lung, Pleura, Thymus and Heart","author":"Nicholson","year":"2015"},{"key":"49","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1097\/PAI.0b013e3181dbfcd2","article-title":"Novel monoclonal antibodies against the proximal (carboxy-terminal) portions of MUC16","volume":"18","author":"Spriggs","year":"2010","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"50","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.ygyno.2004.05.014","article-title":"Wilms Tumor Gene (WT1) and p53 expression in endometrial carcinomas: a study of 130 cases using a tissue microarray","volume":"94","author":"Soslow","year":"2004","journal-title":"Gynecol Oncol"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.20845","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T19:24:49Z","timestamp":1659468289000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.20845"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,12]]},"references-count":50,"journal-issue":{"issue":"44","published-print":{"date-parts":[[2017,9,29]]}},"alternative-id":["20845","29100432"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.20845","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,12]]}}}